Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost ...

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science ...

NAD infusions are just one of the latest crazes for longevity-seekers, but can it really help you live longer? Here’s what an ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

As temperatures rise across the United States, millions will likely face heightened allergy symptoms due to pollen, dust, and ...

Many people take dietary supplements like vitamins and minerals to support their health. However, a recent study from the ...

Corporate Insight (CI), the leading provider of competitive intelligence and customer experience research to the financial services industry, today announced the release of its inaugural DC Plan ...

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

Major study finds specific combination of vitamin D, omega-3s and strength training reduces biological age and slashes cancer ...

The U.S. The Vitamin B3 market is set to witness sustained growth, driven by evolving consumer preferences, technological advancements in vitamin production, and increasing R&D investments. With the ...

StockNews.com lowered shares of ChromaDex (NASDAQ:CDXC – Free Report) from a strong-buy rating to a buy rating in a research ...